Simultaneous estimation of sacubitril and valsartan in bulk and tablet dosage form by rp-hplc

Abstract

Sacubitril is used in treatment of hypertension and coronary  artery  disease  ^[21a,], and valsartan    used for treatment of high blood pressure, of congestive heart failure, and post- myocardialinfarction [21b]. Combination therapy in the treatment of hypertension as an appropriate treatment option is receiving boarder acceptance amongst the clinical community. Mono therapy is often not sufficient to normalize blood pressure since the goal of treatment is to normalize both systolic and diastolic blood pressure. It is proposed that these double combination tablets will be indicated as a substitution therapy in patients (i.e. patients are not to be started on this combination therapy) for the treatment of hypertension. As a replacement therapy in patients whose blood pressure is adequately controlled on Sacubitril and valsartan used as individual or  combinationtherapies.Literature  survey  reveals  the   availability   of   some    methods    for    estimation of Sacubitril (SBL) and valsartan (VAL) includes UV  spectrometry,  RP-HPLC  and  HPTLC alone are in combination with other drugs. Only very few HPLC estimations have been reported in the literature for the determinations of Sacubitril and valsartan present in bulk, formulations and biologicalfluids.The existing methods are inadequate to meet the requirements, hence it is proposed to improve the existing methods and to develop new methods for the simultaneous estimation of Sacubitril and valsartan in pharmaceutical dosage forms.The main objective for that is to improve the conditions and parameters, which could be easily adopted in the validation process.